---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-329520"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2026-08-03T10:50:04+00:00"
generated_at: "2026-08-03T10:55:11.077638+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Indivior Q2 revenue $343M (+14% YoY), raises FY2026 guidance; merger with Supernus expected Q4

## Summary
- Q2 GAAP net income $122M ($0.98 diluted EPS) vs $18M ($0.14) YoY; Non-GAAP net income $142M ($1.15).
- Record SUBLOCADE net revenue $253M (+21% YoY); new patient starts of 32,816 were a record.
- FY2026 guidance raised: total net revenue $1,295M-$1,365M; adjusted EBITDA $700M-$740M (midpoint +68% YoY).
- Repurchased 4.7M shares for $175M in Q2; year-to-date $300M in buybacks.
- Announced all-stock merger of equals with Supernus; expected close in Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-329520
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2026-08-03T10:50:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/0001193125-26-329520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/d118566d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-329520
- JSON: https://secwatch.observer/filing/0001193125-26-329520.json
- Plain text: https://secwatch.observer/filing/0001193125-26-329520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.